Arcutis Biotherapeutics has lined up another celeb to tout the benefits of its topical skin medicine Zoryve, adding world-renowned gymnast Simone Biles to its all-star team of spokespeople.
The company’s “Skin to Believe In” awareness campaign featuring Biles targets the approximately 36 million people in the U.S. who live with inflammatory skin conditions such as seborrheic dermatitis and atopic dermatitis, the most common form of eczema.
Biles herself spent “years” trying different over-the-counter products to calm her itchy, flaking scalp and dry patches on her arms before getting diagnoses from a dermatologist and finding a steroid-free option that works for her in Zoryve, according to Arcutis. Today, the athlete uses Zoryve in its foam formulation for her seb derm and the cream version for her eczema.
“I like Zoryve because it is not a steroid, pill, injection, or shampoo and it's easy to use, not greasy, and fits into my routine,” Biles said in a company release. “Using Zoryve reduced the flakes and itching on my scalp, which bothered me the most, and the eczema spots on my arms are also clearer, too.”
Through “Skin to Believe In,” Biles encourages others who may have the inflammatory skin conditions to bring up the topic with a healthcare provider and seek treatment options.
“I’ve learned that we can’t fix every problem on our own and it’s OK to seek help,” continued Biles. “I believe how you care for yourself reflects how you carry yourself, and by partnering with Arcutis on this awareness campaign I believe we can break the stigma associated with chronic skin conditions by helping people feel empowered to speak with a healthcare provider about their symptoms so that they can find a treatment that works for them.”
According to Arcutis CEO Frank Watanabe, Biles’ first encounter with Zoryve came organically and started on social media. The gymnast opened up about her experience with seborrheic dermatitis and eczema symptoms in a TikTok post around the time of the Paris 2024 Summer Olympics, he explained in an interview. Upon bringing up her itchy, flaky scalp on her large social media platform, dermatologists recognized the seb derm symptoms and encouraged her to check out some of the FDA-approved products available for the condition, which is how she ultimately got started on Zoryve and connected with Arcutis.
“She’s a very enthusiastic supporter of the product,” Watanabe said. “Working with her is great.”
Biles isn’t the only Zoryve spokesperson who organically came across the product. So did professional golfer Max Homa and the mother-daughter duo of actress Tori Spelling and her teenage daughter, Stella McDermott. All three are a part of Arcutis’ recent “Free to Be Me” awareness campaign, which looked to bring attention to the skin conditions and help people who may suffer from them recognize the symptoms.
People with inflammatory skin conditions often don’t realize that they have a treatable medical condition, Watanabe explained, living with symptoms such as itching, sleep disruptions or depression and navigating stigma that can be attached to the visible symptoms of the conditions. Finding a treatment that’s approved for continuous use like Zoryve can be a “real game changer for patients,” the CEO said.
Amongst its peers in the non-steroid, topical dermatitis crowd, Zoryve is the only product that’s also approved in a foam formulation, which can better reach hard-to-treat areas such as the scalp. So far since its 2023 launch, Zoryve foam already makes up over half of the drug’s total sales, pulling down $67.4 million over the second quarter of 2026 compared to the $62.4 million across Zoryve cream’s various dose strengths.
“It’s a really unique product,” Watanabe said of Zoryve foam, adding that it “just fits in with patients’ lives.”
Next year, fast-growing Zoryve could snag another label expansion to cover infants aged three to 24 months with atopic dermatitis, which would be its eighth nod since its initial 2022 approval. This one would cover an area Watanabe knows well; his own son had eczema when he was a baby, meaning he can personally speak to the inconvenience of applying twice-daily topical steroids to young children. Zoryve, meanwhile, has a once-daily application and is already garnering buzz across pediatric dermatologists, who currently “just don’t have good options for these kids,” the CEO said.
Still, there remains work to be done to grow the addressable patient population as more than half of people with psoriasis, seb derm or eczema aren’t currently seeking treatment, Watanabe noted. To help make treatment options available to people who may not have access to local dermatologists, Arcutis this summer launched a virtual health platform that quickly connects patients with independent dermatologists.
“We’re helping to make specialized dermatology care a lot more accessible to patients, no matter where that patient is,” Watanabe explained.
Outside of its awareness campaigns, Zoryve has also been building a name for itself outside of the strictly medical field. This month, Marie Claire magazine bestowed Zoryve cream with its 2026 Best Prescription Skin Solution Award, adding to a stack of similar honors from Allure and Glamour magazine.
Watanabe attributes Zoryve’s unique recognition in the beauty space to “the thoughtful way that we formulated these products” and notes that the skin market itself is a “very patient-driven sector” that’s subject to a different level of patient engagement due to the visibility of the disease and its response to treatment. Given that, awareness campaigns and recognized spokespeople like Biles can “really help motivate people to seek treatment.”
“When you see someone like Simone, who's so relatable and so I think well-liked and respected, talking about her own condition and what she went through, the struggle she went through, and how going to see a dermatology clinician and getting on prescription treatment has really changed her life for the better. I think it helps people demystify it, destigmatize it,” Watanabe said.